The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Ichiro Kinoshita
Honoraria - Bayer; Chugai Pharma; Pfizer
 
Shanu Modi
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Macrogenics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Genentech; Seagen
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seagen; Synta
Travel, Accommodations, Expenses - Daiichi Sankyo; Genentech
 
Junji Tsurutani
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Lilly
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Kirin (Inst); Lilly (Inst); MSD Oncology (Inst); Nihonkayaku (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo; Novartis
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Green Cross; Hanmi; Merck Serono; MSD Oncology; Novartis; Samyang
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Yuta Sato
Employment - Daiichi Sankyo
 
Shunsuke Nakatani
Employment - Daiichi Sankyo/Arqule
 
Caleb C. Lee
Employment - Daiichi Sankyo, Inc.
 
Masahiro Sugihara
Employment - Daiichi-Sankyo Co., LTD.
 
Yasuyuki Okuda
Employment - Daiichi Sankyo
 
Shunji Takahashi
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer/EMD Serono (Inst); PharmaMar (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis